Msefsl

CLOSE X

Risk Disclosures on Derivatives

>9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
>On an average, loss makers registered net trading loss close to ₹ 50,000.
>Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
>Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.

STRIDES PHARMA SCIENCE LTD.

NSE : STARBSE : 532531ISIN CODE : INE939A01011Industry : Pharmaceuticals & DrugsHouse : Private

BSE1503.10110.6 (+7.94 %)

PREV CLOSE ( ) 1392.50

OPEN PRICE ( ) 1432.95

BID PRICE (QTY) 0.00 (0)

OFFER PRICE (QTY) 0.00 (0)

VOLUME 25023

TODAY'S LOW / HIGH ( )1391.30 1528.35

52 WK LOW / HIGH ( )482.5 1675.25

NSE1503.65111.45 (+8.01 %)

PREV CLOSE( ) 1392.20

OPEN PRICE ( ) 1408.80

BID PRICE (QTY) 0.00 (0)

OFFER PRICE (QTY) 1503.65 (713)

VOLUME 618632

TODAY'S LOW / HIGH( ) 1392.30 1529.00

52 WK LOW / HIGH ( )482 1675

Select year

Particulars

Mar 2024

Mar 2023

Mar 2022

Mar 2021

Mar 2020

Operational & Financial Ratios

Earnings Per Share (Rs)

-7.68

-22.44

-51.25

29.93

4.06

CEPS(Rs)

7.85

1.37

-26.87

50.19

24.23

DPS(Rs)

2.50

1.50

0.00

2.50

14.00

Book NAV/Share(Rs)

230.95

242.83

262.48

309.09

281.55

Tax Rate(%)

-27.01

19.32

27.32

11.49

20.71

Margin Ratios

Core EBITDA Margin(%)

11.73

6.17

-0.40

11.45

10.95

EBIT Margin(%)

3.16

-0.40

-8.93

7.77

4.47

Pre Tax Margin(%)

-1.87

-4.58

-12.25

5.03

1.16

PAT Margin (%)

-2.38

-3.70

-8.90

4.45

0.92

Cash Profit Margin (%)

1.15

0.20

-4.53

8.22

4.61

Performance Ratios

ROA(%)

-2.49

-3.52

-6.99

3.82

0.63

ROE(%)

-6.88

-10.15

-18.49

9.21

1.68

ROCE(%)

4.15

-0.49

-9.49

9.08

4.06

Asset Turnover(x)

1.05

0.95

0.78

0.86

0.68

Sales/Fixed Asset(x)

2.02

1.91

1.75

2.04

1.43

Working Capital/Sales(x)

69.65

43.06

-106.88

69.38

-27.04

Efficiency Ratios

Fixed Capital/Sales(x)

0.50

0.52

0.57

0.49

0.70

Receivable days

71.28

73.25

79.41

68.09

74.33

Inventory Days

66.36

67.80

81.35

66.13

64.17

Payable days

204.02

230.40

267.95

264.54

274.24

Valuation Parameters

PER(x)

0.00

28.21

79.39

PCE(x)

99.68

209.18

-12.90

16.83

13.31

Price/Book(x)

3.39

1.18

1.32

2.73

1.15

Yield(%)

0.32

0.52

0.00

0.30

4.34

EV/Net Sales(x)

2.32

1.37

1.86

2.86

1.68

EV/Core EBITDA(x)

12.03

9.69

51.09

13.84

8.11

EV/EBIT(x)

47.67

-201.23

-12.01

22.32

21.93

EV/CE(x)

2.07

1.01

0.85

1.39

0.77

M Cap / Sales

1.78

0.70

1.01

2.28

1.05

Growth Ratio

Net Sales Growth(%)

9.83

20.13

-7.41

20.49

26.33

Core EBITDA Growth(%)

50.42

365.23

-83.70

20.61

100.96

EBIT Growth(%)

888.18

94.73

-211.81

102.24

48.50

PAT Growth(%)

35.67

51.31

-294.53

462.28

-51.42

EPS Growth(%)

65.76

56.22

-271.23

636.70

-88.79

Financial Stability Ratios

Total Debt/Equity(x)

1.14

1.27

1.18

0.76

0.78

Current Ratio(x)

1.03

1.05

0.99

1.03

0.93

Quick Ratio(x)

0.64

0.67

0.64

0.59

0.62

Interest Cover(x)

0.63

-0.10

-2.69

2.84

1.35

Total Debt/Mcap(x)

0.34

1.07

0.90

0.28

0.68